statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cantor Fitzgerald reiterated their overweight rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a research report released on Monday, Benzinga reports. They currently have a $7.00 price...

Humacyte (NASDAQ:HUMA) Receives "Overweight" Rating from Cantor Fitzgerald

Piper Sandler reiterated their neutral rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage...

Humacyte (NASDAQ:HUMA) Earns Neutral Rating from Piper Sandler

Benchmark reissued their buy rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $15.00 price...

Benchmark Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)

DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...

Humacyte to Host Virtual KOL Event  Hemodialysis Access: A Crossroads of Care,  on March 28, 2024

Humacyte (NASDAQ:HUMA  Get Free Report) released its earnings results on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of...

Humacyte (NASDAQ:HUMA) Posts  Earnings Results

Q4 2023 Humacyte Inc Earnings Call Transcript

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Humacyte reports Q4 EPS (24c), consensus (24c)

-Biologics License Application (BLA) for HAV Accepted by FDA on February 8, 2024- -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised...

Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update

Key Financial Metrics Reflect Clinical Advancements and Preparations for Market LaunchRelated Stocks: HUMA...

Humacyte Inc (HUMA) Posts Full Year 2023 Financial Results, Aligns with EPS Projections

Humacyte Q4 2023 Earnings Preview

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Volume	219,017.00
52-Wk High	$5.60
52-Wk Low	$1.96

HUMA Humacyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals